Natera Inc. stocks have been trading up by 10.65 percent after strong clinical trial results boosted investor confidence.
Click Here for a Millionaire's POV on Trading NTRA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- NCCN updated its Bladder Cancer guidelines to include ctDNA-MRD testing with an FDA-approved, tumor-informed assay, giving Signatera a top-tier Category 1 recommendation in muscle-invasive disease.
- The Signatera test now carries an NCCN Category 1 recommendation for guiding adjuvant atezolizumab in MRD-positive muscle-invasive bladder cancer, embedding ctDNA-MRD into standard care.
- BTIG lifted its Natera price target to $270 and reiterated a Buy rating, citing expected oncologist adoption after the NCCN move.
- RBC Capital resumed coverage of Natera with an Outperform rating and a $275 target, pointing to >90% MRD market share and >$1B in annualized Signatera revenue growing over 70% year over year.
- Natera will showcase 21 Prospera transplant studies at the American Transplant Congress, reinforcing its role in non-invasive graft monitoring.
Live Update At 14:03:21 EDT: On Wednesday, June 24, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 10.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Natera Inc. (NTRA) has been trading like a momentum name with real fundamentals behind it. Over the past few weeks, NTRA has climbed from closes around $212–$220 to $259.76 on 2026/06/24. That is a sharp upside move, showing traders are willing to chase strength when catalysts line up.
Intraday on 2026/06/24, NTRA held most of its gains. After an early push from roughly $243 at the open to highs above $261, the stock spent hours grinding between $253 and $261. For active traders, that tight, elevated range signals dip buyers are still in control and shorts are on the back foot.
Fundamentally, Natera is a high-growth, high-valuation diagnostics name. Trailing 12‑month revenue sits near $2.31B, with three- and five-year revenue growth above 40%. Gross margin is a hefty 65.1%, but profitability is still negative, with EBIT margin at -13.1% and return on equity deep in the red. NTRA trades at a rich 11.77x sales and about 16.6x book value, backed by an enterprise value of roughly $33.8B.
More Breaking News
- INFQ Stock Holds Gains As Traders Bet On Volatility
- BMNR Stock Dips As BitMine Lines Up High-Yield Preferred Offering
- BLDR Stock Climbs As Traders Focus On Margins And Momentum
- KEEL Stock Slides As Traders Weigh Losses And Leverage
On the balance sheet, Natera looks liquid: a current ratio of 3 and modest total debt to equity of 0.13. Cash and restricted cash exceed $2B, giving NTRA room to keep funding growth. For traders, this is a classic story: big top-line expansion, strong balance sheet, but losses that demand flawless execution.
Why Traders Are Watching NTRA Right Now
The real driver of NTRA’s latest surge is not just chart momentum. It is the step-change in clinical status for its flagship Signatera MRD test. The National Comprehensive Cancer Network updated its Bladder Cancer guidelines to include ctDNA-MRD testing with an FDA-approved, tumor-informed PCR-NGS assay, effectively handing Signatera a Category 1, highest-level recommendation in muscle-invasive bladder cancer.
That matters. Category 1 means the evidence is strong and there is consensus among experts. For Natera, it turns Signatera from “promising tech” into a guideline-embedded tool for guiding adjuvant immunotherapy decisions. On top of that, the NCCN specifically backs Signatera-guided adjuvant atezolizumab use in MRD-positive patients within a year of cystectomy. Combined with earlier FDA companion diagnostic approval, Natera now has regulatory and guideline lock-in at the same time.
Analysts are reacting. BTIG raised its Natera price target from $250 to $270 and reiterated a Buy rating, explicitly tying the move to Signatera’s NCCN inclusion and future adoption by oncologists. Leerink also reiterated an Outperform view after the guidelines uniquely named Signatera, calling it a key catalyst for broader community oncology uptake, not just in top academic centers.
RBC Capital Markets went further, resuming coverage of Natera with an Outperform rating and a $275 price target. RBC highlights Natera’s dominant >90% share in the high-value oncology MRD space, more than 70% year-over-year growth for Signatera, and over $1B in annualized revenue already flowing from that franchise. That tells traders NTRA is not a tiny speculative story; it is already a scaled leader in MRD.
There is more under the hood. Natera will present 21 studies at the American Transplant Congress, including seven oral presentations, centered on its Prospera donor-derived cell-free DNA test. Data from the PEDAL and ProActive studies show Prospera can predict adverse transplant outcomes even when biopsies are negative, and that low dd-cfDNA levels correlate with much lower rejection and graft loss. That gives Natera a second, transplant-focused growth engine alongside oncology.
Not every tape reaction has been smooth. Despite the NCCN Category 1 win, NTRA actually traded down more than 2% in premarket at one point, a classic “sell the news” move after a strong run. For short-term traders, that’s a reminder that price can diverge from fundamentals in the near term, especially when expectations are elevated. But with multiple firms hiking targets and Natera’s MRD moat solidifying, the fundamental drift still points higher.
Recent Form 4 filings show changes in beneficial ownership by an insider or major holder, but with no details on size or direction. In a story this catalyst-heavy, that vague insider activity sits in the background while guideline wins and analyst calls drive the narrative.
Conclusion
Natera Inc. has entered a new phase, and traders are treating NTRA like a leader, not a lottery ticket. The NCCN Category 1 guideline recommendation for Signatera in muscle-invasive bladder cancer, layered on top of FDA companion diagnostic approval, effectively cements Natera’s MRD technology into standard oncology care in a key indication. Add in >70% year-over-year growth, more than $1B in annualized Signatera revenue, and a >90% MRD share, and you see why BTIG, Leerink, and RBC are lining up with bullish ratings and $270–$275 price targets.
The valuation is not cheap. NTRA trades at premium multiples on sales and cash flow, while margins remain negative. But strong gross margins, robust cash, and consistent free cash flow generation in the latest quarter give Natera time to scale into profitability. Prospera’s expanding transplant data set reinforces that Natera’s story is not one-product dependent.
For active traders, this is exactly the kind of name that rewards preparation. The trend is up, catalysts are real, and the Street is leaning bullish, but pullbacks and “sell the news” flushes are part of the game. As Tim Sykes likes to say, “The market rewards the prepared, not the hopeful.” That mindset lines up with a process-driven approach to trading momentum names like NTRA. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” Studying how NTRA reacts around news, levels, and volume spikes gives traders a cleaner edge than chasing headlines blindly. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.